75 results
8-K
EX-99.1
FATE
Fate Therapeutics Inc
20 Mar 24
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
5:32pm
proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines
8-K
EX-99.1
FATE
Fate Therapeutics Inc
26 Feb 24
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4:03pm
, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off
8-K
EX-99.1
vqb6fg 9vhiyvi
8 Nov 23
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
4:03pm
8-K
EX-99.1
thruyspqs alcpvn
8 Aug 23
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
4:07pm
8-K
EX-99.1
ymycr
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
8-K
EX-99.1
2uyz8eh a3
7 Nov 22
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
1:21pm
8-K
EX-99.1
j4trv7n18e
3 Nov 22
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
EX-99.1
ox37b3auxrzocfknb
3 Aug 22
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
EX-99.1
8coftfqr2o
30 Jun 22
ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration
4:06pm
8-K
EX-99.1
trhjcdtf9kysr0ve
4 May 22
Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
4:06pm